Literature DB >> 18523031

Source of inflammatory markers in patients with atrial fibrillation.

Ioan Liuba1, Henrik Ahlmroth, Lena Jonasson, Anders Englund, Anders Jönsson, Kåge Säfström, Håkan Walfridsson.   

Abstract

AIMS: Elevated levels of C-reactive protein and other inflammatory markers have been reported in some patients with atrial fibrillation (AF). Whether this finding is related to AF per se or to other conditions remains unclear. In addition, the source of inflammatory markers is unknown. Therefore, in the present study, we sought to assess the extent and the source of inflammation in patients with AF and no other concomitant heart or inflammatory conditions. METHODS AND
RESULTS: The study group consisted of 29 patients referred for radiofrequency catheter ablation: 10 patients with paroxysmal AF, 8 patients with permanent AF, and 10 control patients with Wolf-Parkinson-White (WPW) syndrome and no evidence of AF (mean age 54 +/- 11 vs. 57 +/- 13 vs. 43 +/- 16). No patient had structural heart diseases or inflammatory conditions. High-sensitive C-reactive protein, interleukin-6 (IL-6), and interleukin-8 (IL-8) were assessed in blood samples from the femoral vein, right atrium, coronary sinus, and the left and right upper pulmonary veins. All samples were collected before ablation. Compared with controls and patients with paroxysmal AF, patients with permanent AF had higher plasma levels of IL-8 in the samples from the femoral vein, right atrium, and coronary sinus, but not in the samples from the pulmonary veins (median values in the femoral vein: 2.58 vs. 2.97 vs. 4.66 pg/mL, P = 0.003; right atrium: 2.30 vs. 3.06 vs. 3.93 pg/mL, P = 0.013; coronary sinus: 2.85 vs. 3.15 vs. 4.07, P = 0.016). A high-degree correlation existed between the IL-8 levels in these samples (correlation coefficient between 0.929 and 0.976, P < 0.05). No differences in the C-reactive protein and IL-6 levels were noted between the three groups of patients.
CONCLUSION: The normal levels of C-reactive protein and IL-6, along with the elevated levels of IL-8 in patients with permanent AF but not in those with paroxysmal AF, suggest a link between a low-grade inflammatory reaction and long-lasting AF. The elevated IL-8 levels in the peripheral blood, right atrium, and coronary sinus but not in the pulmonary veins suggest a possible source of inflammation in the systemic circulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523031     DOI: 10.1093/europace/eun111

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  28 in total

1.  Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.

Authors:  Mitsuru Seki; Ryan LaCanna; Jeffery C Powers; Christine Vrakas; Fang Liu; Remus Berretta; Geena Chacko; John Holten; Pooja Jadiya; Tao Wang; Jeffery S Arkles; Joshua M Copper; Steven R Houser; Jianhe Huang; Vickas V Patel; Fabio A Recchia
Journal:  J Pharmacol Exp Ther       Date:  2016-06-27       Impact factor: 4.030

Review 2.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 3.  Inflammation and the pathogenesis of atrial fibrillation.

Authors:  Yu-Feng Hu; Yi-Jen Chen; Yenn-Jiang Lin; Shih-Ann Chen
Journal:  Nat Rev Cardiol       Date:  2015-01-27       Impact factor: 32.419

Review 4.  Role of inflammation in atrial fibrillation pathophysiology and management.

Authors:  Masahide Harada; David R Van Wagoner; Stanley Nattel
Journal:  Circ J       Date:  2015-02-16       Impact factor: 2.993

5.  IntravenousCorticosteroid Use Is Associated With Reduced Early Recurrence of Atrial Fibrillation Immediately Following Radiofrequency Catheter Ablation.

Authors:  Nitesh A Sood; Guru M Krishnan; Craig I Coleman; Jeffrey Kluger; Moise Anglade; Christopher A Clyne
Journal:  J Atr Fibrillation       Date:  2011-09-30

Review 6.  Stretch and Inflammation- Their Relation to Fractionation of Electrograms in Atrial Fibrillation.

Authors:  Uma Srivatsa; Mary Chavez Cvt; Sankar Krishnamurthy; L I Zhongmin; Hong Qiu; Nipavan Chiamvimonvat
Journal:  J Atr Fibrillation       Date:  2011-12-20

7.  Intracardiac and extracardiac markers of inflammation during atrial fibrillation.

Authors:  Gregory M Marcus; Lisa M Smith; Karen Ordovas; Melvin M Scheinman; Albert M Kim; Nitish Badhwar; Randall J Lee; Zian H Tseng; Byron K Lee; Jeffrey E Olgin
Journal:  Heart Rhythm       Date:  2009-10-12       Impact factor: 6.343

8.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

9.  High postoperative interleukin-8 levels related to atrial fibrillation in patients undergoing coronary artery bypass surgery.

Authors:  Zhong-Kai Wu; Jari Laurikka; Saila Vikman; Riina Nieminen; Eeva Moilanen; Matti R Tarkka
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

Review 10.  Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins.

Authors:  Ana Catarina Pinho-Gomes; Svetlana Reilly; Ralf P Brandes; Barbara Casadei
Journal:  Antioxid Redox Signal       Date:  2013-10-19       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.